Miłosz Parczewski1, Magdalena Leszczyszyn-Pynka2, Magdalena Witak-Jędra2, Katarzyna Maciejewska2, Weronika Rymer3, Aleksandra Szymczak3, Bartosz Szetela3, Jacek Gąsiorowski3, Monika Bociąga-Jasik4, Paweł Skwara4, Aleksander Garlicki4, Anna Grzeszczuk5, Magdalena Rogalska5, Maria Jankowska6, Małgorzata Lemańska6, Maria Hlebowicz6, Grażyna Barałkiewicz7, Iwona Mozer-Lisewska8, Renata Mazurek9, Władyslaw Lojewski9, Edyta Grąbczewska10, Anita Olczak10, Elżbieta Jabłonowska11, Jeremy Clark12, Anna Urbańska2. 1. Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Arkońska 4, Szczecin, Poland mparczewski@yahoo.co.uk. 2. Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Arkońska 4, Szczecin, Poland. 3. Department of Infectious Diseases, Hepatology and Acquired Immune Deficiencies, Wroclaw Medical University, Koszarowa 5, Wrocław, Poland. 4. Department of Infectious Diseases, Jagiellonian University Medical College, Śniadeckich 5, Kraków, Poland. 5. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Żurawia 14, Białystok, Poland. 6. Department of Infectious Diseases, Medical University in Gdańsk, Smoluchowskiego 18, Gdańsk, Poland. 7. Department of Infectious Diseases, J. Struś Hospital, Szwajcarska 3, Poznań, Poland. 8. Department of Infectious Diseases, Poznan University of Medical Sciences, Szwajcarska 3, Poznań, Poland. 9. Regional Hospital in Zielona Góra, Zyty 26, Zielona Góra, Poland. 10. Department of Infectious Diseases and Hepatology Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Świętego Floriana 12, Bydgoszcz, Poland. 11. Department of Infectious Diseases and Hepatology, Medical University of Łódź, Kniaziewicza 1, Łódź, Poland. 12. Department of Clinical & Molecular Biochemistry, Pomeranian Medical University, Powstańców Wielkopolskich 12, Szczecin, Poland.
Abstract
OBJECTIVES: The surveillance of HIV-transmitted drug resistance mutations (t-DRMs), including temporal trends across subtypes and exposure groups, remains a priority in the current management of the epidemic worldwide. METHODS: A cross-sectional analysis of 833 treatment-naive patients from 9 of 17 Polish HIV treatment centres. Partial pol sequences were used to analyse drug resistance with a general time reversible (GTR)-based maximum likelihood algorithm used for cluster/pair identification. Mutation frequencies and temporal trends were investigated. RESULTS: t-DRMs were observed in 9% of cases (5.8% for NRTI, 1.2% NNRTI and 2.0% PI mutations) and were more common among heterosexually infected (HET) individuals (13.4%) compared with MSM (8.3%, P = 0.03) or injection drug users (IDUs; 2.9%, P = 0.001) and in MSM compared with IDUs (P = 0.046). t-DRMs were more frequent in cases infected with the non-B variant (21.6%) compared with subtype B (6.6%, P < 0.001). With subtype B a higher mutation frequency was found in MSM compared with non-MSM cases (8.3% versus 1.8% for IDU + HET, P = 0.038), while non-B variants were associated with heterosexual exposure (30.4% for HET versus 4.8% for MSM, P = 0.019; versus 0 for IDU, P = 0.016). Trends in t-DRM frequencies were stable over time except for a decrease in NNRTI t-DRMs among MSM (P = 0.0662) and an NRTI t-DRM decrease in HET individuals (P = 0.077). With subtype B a higher frequency of sequence pairs/clusters in MSM (50.4%) was found compared with HET (P < 0.001) and IDUs (P = 0.015). CONCLUSIONS: Despite stable trends over time, patterns of t-DRMs differed notably between transmission categories and subtypes: subtype B was associated with MSM transmission and clustering while in non-B clades t-DRMs were more common and were associated with heterosexual infections.
OBJECTIVES: The surveillance of HIV-transmitted drug resistance mutations (t-DRMs), including temporal trends across subtypes and exposure groups, remains a priority in the current management of the epidemic worldwide. METHODS: A cross-sectional analysis of 833 treatment-naive patients from 9 of 17 Polish HIV treatment centres. Partial pol sequences were used to analyse drug resistance with a general time reversible (GTR)-based maximum likelihood algorithm used for cluster/pair identification. Mutation frequencies and temporal trends were investigated. RESULTS: t-DRMs were observed in 9% of cases (5.8% for NRTI, 1.2% NNRTI and 2.0% PI mutations) and were more common among heterosexually infected (HET) individuals (13.4%) compared with MSM (8.3%, P = 0.03) or injection drug users (IDUs; 2.9%, P = 0.001) and in MSM compared with IDUs (P = 0.046). t-DRMs were more frequent in cases infected with the non-B variant (21.6%) compared with subtype B (6.6%, P < 0.001). With subtype B a higher mutation frequency was found in MSM compared with non-MSM cases (8.3% versus 1.8% for IDU + HET, P = 0.038), while non-B variants were associated with heterosexual exposure (30.4% for HET versus 4.8% for MSM, P = 0.019; versus 0 for IDU, P = 0.016). Trends in t-DRM frequencies were stable over time except for a decrease in NNRTI t-DRMs among MSM (P = 0.0662) and an NRTI t-DRM decrease in HET individuals (P = 0.077). With subtype B a higher frequency of sequence pairs/clusters in MSM (50.4%) was found compared with HET (P < 0.001) and IDUs (P = 0.015). CONCLUSIONS: Despite stable trends over time, patterns of t-DRMs differed notably between transmission categories and subtypes: subtype B was associated with MSM transmission and clustering while in non-B clades t-DRMs were more common and were associated with heterosexual infections.
Authors: Joanna Smoleń-Dzirba; Magdalena Rosińska; Piotr Kruszyński; Jolanta Bratosiewicz-Wąsik; Robert Wojtyczka; Janusz Janiec; Bartosz Szetela; Marek Beniowski; Monika Bociąga-Jasik; Elżbieta Jabłonowska; Tomasz J Wąsik; And The Cascade Collaboration In EuroCoord Journal: Med Sci Monit Date: 2017-02-07
Authors: Miłosz Parczewski; Magdalena Leszczyszyn-Pynka; Magdalena Witak-Jędra; Bartosz Szetela; Jacek Gąsiorowski; Brygida Knysz; Monika Bociąga-Jasik; Paweł Skwara; Anna Grzeszczuk; Maria Jankowska; Grażyna Barałkiewicz; Iwona Mozer-Lisewska; Władysław Łojewski; Katarzyna Kozieł; Edyta Grąbczewska; Elżbieta Jabłonowska; Anna Urbańska Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Philip J Palumbo; Yinfeng Zhang; Jessica M Fogel; Xu Guo; William Clarke; Autumn Breaud; Paul Richardson; Estelle Piwowar-Manning; Stephen Hart; Erica L Hamilton; Ngo T K Hoa; Mariya Liulchuk; Latifah Anandari; Tran Viet Ha; Kostyantyn Dumchev; Zubairi Djoerban; Irving Hoffman; Brett Hanscom; William C Miller; Susan H Eshleman Journal: PLoS One Date: 2019-10-10 Impact factor: 3.240
Authors: Y X Song; R L Xin; Z C Li; H W Yu; W H Lun; J Ye; A Liu; A X Li; J W Li; J Z Ye; M Q Hao; H Y Lu; L J Sun Journal: Epidemiol Infect Date: 2018-01-18 Impact factor: 4.434